J 2019

Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry

MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Jiří VÍTOVEC, Ales LINHART et. al.

Basic information

Original name

Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry

Authors

MIKLÍKOVÁ, Marie (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Jiří VÍTOVEC (203 Czech Republic, belonging to the institution), Ales LINHART (203 Czech Republic), Petr WIDIMSKY (203 Czech Republic), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Kamil ZEMAN (203 Czech Republic), Jan BELOHLAVEK (203 Czech Republic), Filip MALEK, Marián FELŠŐCI (703 Slovakia, belonging to the institution), Jiri KETTNER (203 Czech Republic), Petr OSTADAL (203 Czech Republic), Cestmir CIHALIK (203 Czech Republic), Jiří ŠPÁC (203 Czech Republic, belonging to the institution), Hikmet AL-HITI (203 Czech Republic), Marian FEDORCO (203 Czech Republic), Richard FOJT, Andreas KRUGER (203 Czech Republic), Josef MALEK (203 Czech Republic), Tereza MIKUSOVA (203 Czech Republic), Zdenek MONHART (203 Czech Republic), Stanislava BOHACOVA (203 Czech Republic), Lidka POHLUDKOVA (203 Czech Republic), Filip ROHAC (203 Czech Republic), Jan VACLAVIK (203 Czech Republic), Dagmar VONDRAKOVA (203 Czech Republic), Klaudia VYSKOCILOVA (203 Czech Republic), Miroslav BAMBUCH, Gabriela DOSTALOVA, Stepan HAVRANEK, Ivana SVOBODOVÁ (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Roman MIKLIK (guarantor) and Jiří PAŘENICA (203 Czech Republic, belonging to the institution)

Edition

Clinical Cardiology, Hoboken, John Wiley and Sons Inc. 2019, 0160-9289

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.248

RIV identification code

RIV/00216224:14110/19:00110765

Organization unit

Faculty of Medicine

UT WoS

000478082600003

Keywords in English

acute heart failure; AHEAD; allopurinol

Tags

International impact, Reviewed
Změněno: 24/9/2019 08:47, Mgr. Tereza Miškechová

Abstract

V originále

Background Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA >= 500 mu moL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. Results In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). Conclusion Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.

Links

MUNI/A/1250/2017, interní kód MU
Name: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii
Investor: Masaryk University, Category A